Canadian drug policy researcher Alan Cassels observes October as breast cancer awareness month by analyzing the hype of breast cancer drug Herceptin. He writes: “The media pushed the glee meter into the red zone, with words like ‘breakthrough,’ ‘wonder drug,’ and ‘impressive advance,’ overblown, laudatory adjectives that I admonish journalism students to strenuously avoid.”
Cassels concludes his column: “We all want new and better breast cancer treatments, but that doesn’t mean we should allow selective and misleading reports of a drug’s benefits to drain our public health care system of precious dollars, and put suffering patients on a roller coaster of hope and despair.”
Opinions on other issues in news, journals, PR, advertising, marketing
The world is watching US.
Since Sep 2018, at least 7 children have died in US custody, including 3 from influenza-related complications.
"Outbreaks & deaths in detention centers point to the need for influenza immunization in these facilities"
And more
https://www.nejm.org/doi/full/10.1056/NEJMp1916894#.XjJFqg9wXys.twitter
More for milk debates: "Switching to skim #milk may slow biological aging" https://upi.com/6975065t via @upi cc @garyschwitzer @joansalgeblake
"We can't say that this was caused by milk fat." As is often the case with nutrition studies: correlation ≠ causation.
#RelaxDammit
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
rebecca farmer
October 5, 2005 at 1:41 pmHi, I think you’ve posted on the Think Before You Pink campaign in the past, and I wanted to let you know that the newest phase of the campaign has launched and is available online at http://www.thinkbeforeyoupink.org. This year’s campaign is focused on all the pink ribbon products on the market and asking the companies that sell them to be forthcoming about how much money they actually give to breast cancer, etc.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like